Alcon acquires Neurotech and Encelto, the only FDA-approved treatment for MacTel type 2
ALC•Alcon acquired Neurotech and Encelto, described as the only FDA-approved treatment for MacTel type 2.
1. Acquisition announced
Alcon acquired Neurotech and Encelto, the only FDA-approved treatment for MacTel type 2.
